NCT00051935View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

April 30, 2003

Study Completion Date

October 31, 2003

Conditions
Glycogen Storage Disease Type IIPompe DiseaseAcid Maltase Deficiency DiseaseGlycogenosis 2
Interventions
DRUG

Alglucosidase alfa

20 mg/kg (qow); intravenous

Trial Locations (1)

08903-0591

Saint Peter's University Hospital, New Brunswick

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00051935 - A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II | Biotech Hunter | Biotech Hunter